ir_header
Current stock value

Last updated on Nov 21, 2014 3:59 PM ET

NASDAQ : SPHS 2.16   
- 0.18
  
7.69%

Fact Sheet

PDF Download the Sophiris Fact Sheet


Investor Presentation

PDF Download the Sophiris Investor Presentation


Investors

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is currently enrolling patients in the PLUS 1 Phase III clinical study using PRX302 for the treatment of symptoms of BPH.

View all »   RSSRecent Releases

Nov 12, 2014
Sophiris Bio Reports Third Quarter Financial Results

Nov 7, 2014
Sophiris Bio to Present at the Stifel 2014 Healthcare Conference

View all »Events & Presentations

Dec 2, 2014 at 12:50 PM ET
Piper Jaffray Annual Healthcare Conference